CNS
- Ref-No.Technology
- 01-00903Novel method for direct neuronal reprogramming
- 01-00987DMD Gene Therapy Approach
- 03-00128New Key Drug Target for Psychiatric Disorders
- 03-00317Novel inhibitors of amyloid aggregate formation
- 03-00341KCNQ4 and KCNQ5 ion channels for the identification of selective channel function modulators
- 03-00363Small molecule inhibitors of STOML3 promise to treat neuropathic pain
- 03-00367Targeting of Autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in Alzheimer’s and vascular dementia
- 10-00107Barnesins – novel natural small molecules as highly specific cysteine protease inhibitors
- 11-00057Innovative Nerve Sheath Tumor Therapy
- 15-00006Biocompatible nerve guidance conduit for neuroregeneration
- 15-00247Methylation biomarker to predict the response to monoaminergic antidepressants
- 15-00603Endoscopic device for stimulation of the laryngeal adductor reflex
- 16-00012SUCLG2 as determinator of CSF Aβ1-42 levels and attenuator of cognitive decline in Alzheimer’s disease
- 21-00002SynProt-A database for the proteome of synaptic junctions
- 21-00011Innovative diagnostic agent for high resolution mapping of acute cerebral ischemia
- 21-00022Novel device for minimally-invasive optical stimulation of nerve cells
- 21-00027Ferulic acid derivative FAE-20 as efficient neuroprotective agent and memory enhancer
- 23-00054Reduction of α-synuclein toxicity using PDE-1 inhibitor as a novel treatment in neurodegenerative synucleinopathies
- 23-00064Treating dementia and other brain disorders with natural glycans
- 23-00065Novel treatment of dementia-associated tauopathies
- 23-00069NMDAR targeted CAAR-T cell therapy
- 24-00004PET-tracer for early diagnosis of Alzheimer's disease
- 43-00006Genetically engineered human 3D brain tumor models for disease modeling and compound evaluation
